1. Local Delivery Of Irinotecan To Recurrent Glioblastoma At Reoperation Offers A Safe Therapeutic Advantage Over Systemic Delivery. (31st January 2018) Authors: Cruickshank, Garth; Ngoga, Desire; Detta, Allah; Lewis, Andy; Holden, Rebecca; Fayaye, Olufawe Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 1 Page Start: i1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗